Holen Sie sich die Stockscreener-App
13.00
5.93%
-0.82
Schlusskurs vom Vortag:
$13.82
Offen:
$14.01
24-Stunden-Volumen:
351.34K
Relative Volume:
0.87
Marktkapitalisierung:
$707.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.56%
1M Leistung:
+7.62%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.69
$14.13
1-Wochen-Bereich:
$12.38
$14.42
52-Wochen-Spanne:
$11.10
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-785-8308
Adresse
245 MAIN STREET, CAMBRIDGE
Vergleichen Sie BCAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
13.00 | 707.40M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus PT from Analysts - Defense World
Bicara Therapeutic, Inc. announced that it has received $108.234983 million in funding from a group of investors - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Receives Outperform Rating from Wedbush - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 8.6%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 7.3%Should You Buy? - MarketBeat
Wedbush Reiterates Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Announces First Patients Enrolled in - GlobeNewswire
Major Cancer Treatment Breakthrough? Phase 2/3 Trial Launches for Advanced Head & Neck Cancer - StockTitan
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to Strong-Buy at Wedbush - MarketBeat
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Wedbush - MarketBeat
Wedbush Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wedbush Upgrades Bicara Therapeutics (NASDAQ:BCAX) to “Strong-Buy” - Armenian Reporter
Bicara Therapeutics (BCAX) to Release Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - Nasdaq
Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 9.7%Should You Buy? - MarketBeat
Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN
Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me (NASDAQ:BCAX) - Seeking Alpha
H.C. Wainwright lifts Bicara stock target to $45, maintains buy - MSN
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowTime to Sell? - MarketBeat
Bicara Therapeutics price target raised to $45 from $42 at H.C. Wainwright - MSN
Bicara Therapeutics Presents Phase 1/1B Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal At the 2025 Asco Gastrointestinal Cancers Symposium - Marketscreener.com
Stifel maintains Buy on Bicara stock with $47 target By Investing.com - Investing.com Canada
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 at HC Wainwright - Defense World
Bicara reports positive Phase 1/1b trial results for cancer therapy By Investing.com - Investing.com South Africa
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up After Analyst Upgrade - Defense World
Bicara Therapeutics Presents Phase 1/1b Dose Expansion - GlobeNewswire
Stifel maintains Buy on Bicara stock with $47 target - Investing.com India
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up on Analyst Upgrade - MarketBeat
H.C. Wainwright lifts Bicara stock target to $45, maintains buy By Investing.com - Investing.com Australia
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $45.00 - MarketBeat
Cantor Fitzgerald Weighs in on BCAX FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on BCAX FY2025 Earnings - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.00 Average Price Target from Analysts - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month LowHere's What Happened - MarketBeat
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Bicara Therapeutics Inc-Aktie (BCAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Flynn James E | Possible Members of 10% Group |
Sep 17 '24 |
Buy |
18.00 |
70,000 |
1,260,000 |
897,587 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):